The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.
By: Robert Glanzman, MD
Published: March 17, 2020
“For us, what we’re doing is we’re either donating or receiving electrons directly within cells to drive bioenergetic reactions—the formation of energy within the cell.”
Clene Nanomedicine’s investigational agent, CNM-Au8, has set itself apart from other pipeline products by showing a reduction of neurodegeneration in animal models of diseases like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). No other approved therapies for the treatment of MS have been shown to remyelinate chronic MS lesions, and similarly, no therapies have been shown to slow disease progression across MS, Parkinson disease (PD), nor ALS.
CNM-Au8 is absorbed in the blood stream and dispersed throughout the organ system. Robert Glanzman, MD, chief medical officer, Clene Nanomedicine, described the distinct nanosized crystalized formula as a “bioenergetic catalyst support,” aiming to reduce reaction energy and push other reactions forward.
To find out more about CNM-Au8 and its unique development background, NeurologyLive sat down with Glanzman at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum, February 27-29, 2020, in West Palm Beach, Florida. He detailed the reparative and protective characteristics of the drug.